Want to see HK:2509 full AI Analyst Report?
Top Page
Qyuns Therapeutics Co., Ltd. Class H
(2509)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$18.50
▼(-35.27% Downside)
Action:Upgraded
Date:09/06/26
The score is driven primarily by the sharp improvement in financial performance (strong margins and solid free cash flow) and a low P/E valuation. Offsetting these positives, technical indicators are neutral-to-weak with the price below key moving averages, and the recent profitability/cash flow turnaround is still relatively new given the prior multi-year loss history.
Positive Factors
Strong profitability improvement
The latest period shows a major improvement in scale and profitability, with strong revenue growth and unusually high margins. If these economics persist, they can support reinvestment, strengthen operating resilience, and create meaningful earnings capacity over the next several quarters.
Negative Factors
Profitability turnaround is unproven
The current earnings surge follows several years of substantial losses, so its durability has not yet been demonstrated through a full operating cycle. Any reversal in revenue or margins could expose the company to renewed losses and make earnings more volatile.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong profitability improvement
The latest period shows a major improvement in scale and profitability, with strong revenue growth and unusually high margins. If these economics persist, they can support reinvestment, strengthen operating resilience, and create meaningful earnings capacity over the next several quarters.
Read all positive factors
Qyuns Therapeutics Co., Ltd. Class H (2509) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.73B
Dividend YieldN/A
Average Volume (3M)102.17K
Price to Earnings (P/E)5.7
Beta (1Y)0.56
Revenue Growth230.35%
EPS GrowthN/A
CountryHK
Employees337
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.42
Shares Outstanding227,071,600
10 Day Avg. Volume48,660
30 Day Avg. Volume102,173
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.43
Price to Sales (P/S)4.80
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.88
Revenue Forecast (FY)HK$522.00M
Qyuns Therapeutics Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Qyuns Therapeutics Co., Ltd., a biotechnology company established in 2015 and headquartered in Taizhou, China, is focused on the discovery and clinical advancement of biologic therapies. Its primary mission is to address autoimmune and allergic di...
Qyuns Therapeutics Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
69
Positive
Cash Flow
85
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.02B | 786.08M | 158.79M | 14.75M | 9.66M | 21.35M |
| Gross Profit | 908.13M | 664.66M | 92.19M | 14.75M | -25.85M | -9.56M |
| EBITDA | 581.34M | 351.00M | -311.82M | -484.12M | -295.51M | -155.65M |
| Net Income | 546.10M | 306.31M | -335.57M | -507.75M | -298.19M | -411.04M |
Balance Sheet | ||||||
| Total Assets | 1.91B | 1.60B | 983.88M | 795.58M | 1.16B | 1.31B |
| Cash, Cash Equivalents and Short-Term Investments | 1.04B | 1.04B | 556.55M | 377.25M | 689.57M | 620.44M |
| Total Debt | 686.50M | 580.26M | 527.60M | 346.06M | 295.25M | 290.26M |
| Total Liabilities | 1.07B | 921.62M | 762.83M | 494.63M | 419.55M | 444.45M |
| Stockholders Equity | 861.02M | 694.33M | 228.98M | 324.54M | 641.72M | 670.35M |
Cash Flow | ||||||
| Free Cash Flow | 515.88M | 392.23M | -186.09M | -308.63M | -301.70M | -228.64M |
| Operating Cash Flow | 519.90M | 399.85M | -186.09M | -300.68M | -275.23M | -157.60M |
| Investing Cash Flow | -632.10M | 118.69M | -25.23M | 243.11M | -5.70M | -306.69M |
| Financing Cash Flow | -51.91M | 93.73M | 351.81M | 61.21M | 211.49M | 281.48M |
Qyuns Therapeutics Co., Ltd. Class H Technical Analysis
Negative
28.58
Price Trends
16.50
Negative
16.34
Negative
18.12
Negative
Market Momentum
-0.09
Positive
44.09
Neutral
27.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2509, the sentiment is Negative. The current price of 28.58 is above the 20-day moving average (MA) of 16.75, above the 50-day MA of 16.50, and above the 200-day MA of 18.12, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 44.09 is Neutral, neither overbought nor oversold. The STOCH value of 27.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2509.
Qyuns Therapeutics Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$3.73B | 5.73 | 70.24% | ― | 230.35% | ― | |
59 Neutral | HK$3.51B | 4.73 | 10.99% | ― | 1417.68% | 660.14% | |
52 Neutral | HK$4.77B | 7.59 | 47.76% | ― | 286.20% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$2.19B | 35.65 | 6.51% | ― | 605.95% | ― | |
47 Neutral | HK$2.81B | -5.16 | -32.32% | ― | 28.93% | 27.27% | |
44 Neutral | HK$7.41B | -66.76 | -9.49% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
HK:2509
Qyuns Therapeutics Co., Ltd. Class H
16.24
-16.06
-49.72%
HK:6996
Antengene Corporation Limited
3.34
-3.74
-52.82%
HK:6998
Genor Biopharma Holdings Limited
1.70
-3.15
-64.95%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
5.78
-5.18
-47.26%
HK:2171
CARsgen Therapeutics Holdings Ltd.
12.55
-8.99
-41.74%
HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
3.21
-9.00
-73.73%
Qyuns Therapeutics Co., Ltd. Class H Corporate Events
Qyuns Therapeutics Swings to Interim Profit on Surging Licensing Revenue
Aug 19, 2026
Qyuns Therapeutics reported a sharp increase in unaudited interim revenue to RMB424.1 million for the six months ended June 30, 2026, driven mainly by RMB378.6 million in licensing income from overseas deals for QX027N and milestones for QX008N an...
Qyuns Therapeutics Sets Board Meeting to Approve 2026 Interim Results
Aug 7, 2026
Qyuns Therapeutics Co., Ltd. has scheduled a board meeting for August 19, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The meeting will also address other c...
Qyuns Therapeutics Wins New QX027N Trial Approvals and Secures Global Licensing Deal
Jul 31, 2026
Qyuns Therapeutics announced that its long-acting bispecific antibody QX027N has received clinical trial approvals in China for chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyps, adding two new respiratory indicati...
Caldera-Synlogic Merger and $278 Million Raise Bolster Qyuns-Linked IBD Program
Jul 29, 2026
Caldera Therapeutics, Qyuns Therapeutics’ partner for the investigational IBD drug QX030N/CLD-423, has agreed to merge with Synlogic in an all-stock deal that will create a new holding company listed on the Nasdaq Capital Market under the ti...
Qyuns Therapeutics to Fully Acquire Cellularforce in RMB86 Million Connected Deal
Jun 26, 2026
Qyuns Therapeutics has moved to fully consolidate its subsidiary Cellularforce by acquiring the remaining 34.0001% equity stake from Taizhou Huacheng for RMB86.02 million through its wholly owned unit Saifu Juli. The deal, priced via a public list...
Qyuns Therapeutics Launches Share Buyback to Address Undervaluation Concerns
Jun 9, 2026
Qyuns Therapeutics Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical company, develops therapeutic products within the healthcare and life sciences sector and is led by chairman and executive director Qiu Jiwan. The company aims to attract i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.